IE 11 is not supported. For an optimal experience visit our site on another browser.

Achillion to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., May 20, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will be presenting a company overview at two upcoming investor conferences:
/ Source: GlobeNewswire

NEW HAVEN, Conn., May 20, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will be presenting a company overview at two upcoming investor conferences:

  • ThinkEquity 2nd Annual Healthcare Conference on Wednesday, May 25, 2011 at 12:30 p.m. EDT at The Princeton Club in New York City, NY; and
  • Jefferies 2011 Global Healthcare Conference on Monday, June 6, 2011 at 2:30 p.m. EDT at the Grand Hyatt in New York City, NY.

The live audio broadcasts and the subsequent archived webcasts of the Company's presentations will be available on the Company's website, http://www.achillion.com, under the "News Center" section. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit or call 1-203-624-7000.

CONTACT: Company Contact: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 gschulman@achillion.com Investors: Mary Kay Fenton Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 mfenton@achillion.com Media: Christin Culotta Miller Ogilvy PR Tel. (212) 880-5264 Christin.Miller@OgilvyPR.com